Marijuana Stock Movers For May 1, 2024
GAINERS: Global Hemp Group (OTC:GBHPF) shares closed up 86.36% at $0.04 Pharmadrug (OTC:LMLLF) shares closed up 18.72% at…
Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss
Cannara Biotech Inc. announced on Monday its fiscal second quarter 2024 financial and operating results for the three and six-month periods ended Feb. 29, 2024. The company reported a 68% year-over-year increase in revenues for the first half of fiscal 2024, a metrics CFO Nicholas Sosiak called "a testament to our growing influence in the Quebec, Ontario, Alberta, and BC markets." "Our proactive steps towards streamlining assets align with our ambition to fortify our financial foundation as we relentlessly stay focused on gaining market share and becoming the leader in Canada, the second-largest cannabis market in the world," Sosiak said. "As for our long-term vision, we do see our future extend beyond our borders where Cannara is a globally recognized brand synonymous with excellence and value in cannabis."
Billions On The Move: Tracking Market Cap Changes In Top Cannabis Firms After DEA Rescheduling Announcement
Tuesday's announcement that the DEA is moving towards rescheduling cannabis from Schedule I to Schedule III, has already injected billions into the publicly traded market for cannabis companies.
What’s Going On With Weed Stocks Canopy Growth, Aurora Cannabis And Tilray?
Cannabis stocks saw a short-lived rally Tuesday following reports that the DEA will move to reschedule marijuana from a Schedule I to a Schedule III substance. The DEA's proposal would recognize the medical uses of cannabis and acknowledge it has less potential for abuse than Schedule I substances.
DEA Moves To Reschedule Weed, Cannabis Stocks Go For Wild Ride, Pummel Short Sellers With $210M In Losses
Cannabis stocks soared following Tuesday's news that the DEA intends to designate marijuana from Schedule I to Schedule III.
What’s Going On With IM Cannabis Stock?
Cannabis stocks soared Tuesday following reports that the DEA will move to reschedule marijuana from a Schedule I to a Schedule III substance. IM Cannabis shares are holding the gains, while larger weed stocks including Canopy Growth Corporation, Aurora Cannabis, Inc. and Tilray Brands, Inc. are dropping Wednesday.
Safe Harbor Financial Issues Statement On Cannabis Rescheduling
The profound impact of rescheduling cannabis from Schedule I to Schedule III signifies a crucial shift in the perception of cannabis, recognizing its medical potential and solidifying its legitimacy in the financial
Cannabis Stocks React To DEA Rescheduling: Canopy & Aurora Surge, Tilray, WM Tech Hold Steady
In a historic trading session on Tuesday, cannabis stocks soared following the DEA's decision to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act.
Bullish Tuesday For Marijuana Stocks – Elixinol Wellness, Item 9 Labs Among Top Gainers
GAINERS: Elixinol Wellness (OTC:ELLXF) shares closed up 110.00% at $0.01 Item 9 Labs (OTC:INLB) shares closed up 100.00%…
Cannabis Industry Leaders React To DEA’s Historic Rescheduling of Cannabis
the U.S. Drug Enforcement Administration (DEA) is reportedly moving cannabis from Schedule I to Schedule III